12/4
01:01 pm
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at Benchmark Co..
12/3
03:38 pm
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
High
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
12/3
02:05 pm
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
High
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/3
08:00 am
clnn
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
High
Report
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
12/2
05:39 pm
clnn
Clene to Provide CNM-Au8® ALS Program Update
High
Report
Clene to Provide CNM-Au8® ALS Program Update
11/28
06:12 am
clnn
Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company [Yahoo! Finance]
Low
Report
Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company [Yahoo! Finance]
11/20
08:36 am
clnn
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference [Yahoo! Finance]
Medium
Report
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference [Yahoo! Finance]
11/20
08:00 am
clnn
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Medium
Report
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
11/17
08:43 am
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
Low
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
11/14
05:24 am
clnn
Clene GAAP EPS of -$0.85 misses by $0.27, revenue of $0.02M misses by $0.04M [Seeking Alpha]
High
Report
Clene GAAP EPS of -$0.85 misses by $0.27, revenue of $0.02M misses by $0.04M [Seeking Alpha]
11/13
10:31 am
clnn
Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
High
Report
Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/13
08:38 am
clnn
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights [Yahoo! Finance]
High
Report
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights [Yahoo! Finance]
11/13
08:00 am
clnn
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
High
Report
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
10/20
08:30 am
clnn
Clene to Present at the Emerging Growth Conference
Medium
Report
Clene to Present at the Emerging Growth Conference
10/15
08:30 am
clnn
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Low
Report
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
9/25
08:22 am
clnn
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
Medium
Report
Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.
9/25
08:19 am
clnn
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients [Yahoo! Finance]
Low
Report
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients [Yahoo! Finance]
9/25
08:00 am
clnn
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Medium
Report
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
9/10
08:25 am
clnn
Clene (NASDAQ:CLNN) had its price target lowered by analysts at Benchmark Co. from $33.00 to $31.00. They now have a "buy" rating on the stock.
Medium
Report
Clene (NASDAQ:CLNN) had its price target lowered by analysts at Benchmark Co. from $33.00 to $31.00. They now have a "buy" rating on the stock.